Figure 2.

Targets for cancer immunotherapies in Ewing sarcoma. Extracellular targets are natively expressed on the surface of Ewing sarcoma cells and can be targeted by both cellular and non-cellular immunotherapies. These therapies include CAR T cells, monoclonal antibodies (mAbs) and bispecific T cell engagers. In contrast, intracellular targets require presentation of naturally processed peptides in an HLA context and cellular immunotherapies such as transgenic T cell receptor (TCR) T cells, cancer vaccine or autologous tumor-infiltrating lymphocytes. CAR, chimeric antigen receptor; TCR, T cell receptor.